Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

313.85
-1.4600-0.46%
Post-market: 313.850.00000.00%19:33 EDT
Volume:354.88K
Turnover:110.30M
Market Cap:18.98B
PE:34.07
High:314.43
Open:313.87
Low:308.53
Close:315.31
52wk High:330.75
52wk Low:263.00
Shares:60.49M
Float Shares:60.49M
Volume Ratio:1.52
T/O Rate:0.59%
Dividend:4.60
Dividend Rate:1.47%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.96
PE(LYR):7.56

Loading ...

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30